For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Menu
Weill Cornell Medicine Multiple Sclerosis Center

You are here

Home > Publications
Found 9 results
Author Title [ Type(Desc)] Year
Filters: Filter is   [Clear All Filters]
Journal Article
Kaunzner UW, Salamon E, Pentsova E, Rosenblum M, Karimi S, Nealon N, Lavi E, Jamieson DG.  2017.  An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.. J Neuroimaging. 27(3):306-311.
Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..  2017.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.
Eskreis-Winkler S, Zhou D, Liu T, Gupta A, Gauthier SA, Wang Y, Spincemaille P.  2017.  On the influence of zero-padding on the nonlinear operations in Quantitative Susceptibility Mapping.. Magn Reson Imaging. 35:154-159.
Dayan M, Rúa SMHurtado, Monohan E, Fujimoto K, Pandya S, LoCastro EM, Vartanian T, Nguyen TD, Raj A, Gauthier SA.  2017.  MRI Analysis of White Matter Myelin Water Content in Multiple Sclerosis: A Novel Approach Applied to Finding Correlates of Cortical Thinning.. Front Neurosci. 11:284.
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.
Rumah KR, Vartanian T, Fischetti VA.  2017.  Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens.. Front Cell Infect Microbiol. 7:11.
Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon N, Vartanian T, Perumal J.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.